For Immediate Release. Chicago, IL – July 17, 2024 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk NVO, Merck MRK and Pfizer PFE.

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

By Sam Boughedda. Jefferies analysts initiated Eli Lilly & Co. (NYSE: LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE: MRK) with a Buy rating and $125 price target in ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

January was a big month for pharmaceutical stocks, with Merck(NYSE: MRK), Eli Lilly(NYSE: LLY), and Novo Nordisk(NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market ...